Die Übersetzung dieser Seite ist experimentell und in Entwicklung. Wir freuen uns über Ihr !
Elevance Health Zukünftiges Wachstum
Future Kriterienprüfungen 2/6
Elevance Health wird ein jährliches Gewinn- und Umsatzwachstum von 12.3% bzw. 5.1% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 14.2% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 20.1% betragen.
Wichtige Informationen
12.2%
Wachstumsrate der Gewinne
14.2%
EPS-Wachstumsrate
| Healthcare Gewinnwachstum | 17.3% |
| Wachstumsrate der Einnahmen | 5.1% |
| Zukünftige Eigenkapitalrendite | 20.1% |
| Analystenabdeckung | Good |
| Zuletzt aktualisiert | 04 Jun 2024 |
Jüngste Aktualisierungen zum künftigen Wachstum
Recent updates
Elevance Health's (NYSE:ELV) Returns On Capital Are Heading Higher
May 27
We Think Shareholders Will Probably Be Generous With Elevance Health, Inc.'s (NYSE:ELV) CEO Compensation
May 09Elevance Health (NYSE:ELV) Has Announced A Dividend Of $1.63
Apr 25Elevance Health: It's Not Too Late To Buy Their Dividend Growth
Apr 23Is Elevance Health (NYSE:ELV) Using Too Much Debt?
Apr 16Elevance Health: Not Doing Enough In 2024 To Justify Premium Price
Apr 11Elevance Health, Inc.'s (NYSE:ELV) Earnings Haven't Escaped The Attention Of Investors
Apr 01Elevance: A Healthy Dose Of Dividend Growth
Mar 21Elevance Heath: Financial Growth And Technical Strength Indicate A Buy
Mar 07Elevance Health (NYSE:ELV) Will Pay A Larger Dividend Than Last Year At $1.63
Feb 19Elevance Health: Time To Buy This Incredible Dividend Growth Stock
Jan 26Slowing Rates Of Return At Elevance Health (NYSE:ELV) Leave Little Room For Excitement
Jan 19Is Elevance Health (NYSE:ELV) A Risky Investment?
Jan 02Elevance Health, Inc.'s (NYSE:ELV) Shares Not Telling The Full Story
Dec 18A Look At Elevance's Margin Dynamics
Nov 23Is It Time To Consider Buying Elevance Health, Inc. (NYSE:ELV)?
Nov 16Elevance Health: A High Conviction Defensive Blue Chip Buy
Oct 19These 4 Measures Indicate That Elevance Health (NYSE:ELV) Is Using Debt Safely
Oct 04Elevance: Pave The Way For The Next UnitedHealth
Sep 21Elevance Health (NYSE:ELV) Is Experiencing Growth In Returns On Capital
Sep 18Here's The Price I Would Buy Elevance Health Stock
Sep 13If EPS Growth Is Important To You, Elevance Health (NYSE:ELV) Presents An Opportunity
Aug 18Is Now The Time To Look At Buying Elevance Health, Inc. (NYSE:ELV)?
Aug 04Narrowing Down High-Quality Dividend Growth: Elevance Health Is Elemental
Jul 24Elevance Health: Beaten Down Share Price Offers Solid Potential
Jul 10Here's Why Elevance Health (NYSE:ELV) Can Manage Its Debt Responsibly
Jul 05Elevance Health: A Critical Update (Rating Downgrade)
Jun 05Elevance Health's (NYSE:ELV) Returns On Capital Are Heading Higher
Jun 04Is Now The Time To Look At Buying Elevance Health, Inc. (NYSE:ELV)?
May 05We Think Elevance Health (NYSE:ELV) Can Stay On Top Of Its Debt
Apr 04Elevance Health's (NYSE:ELV) Dividend Will Be Increased To $1.48
Feb 17Elevance Health (NYSE:ELV) Is Experiencing Growth In Returns On Capital
Feb 13Elevance Health: Attractive On Its Expansion Catalysts
Feb 09Elevance Health (NYSE:ELV) Has Announced That It Will Be Increasing Its Dividend To $1.48
Jan 28Elevance Health acquiring Blue Cross and Blue Shield of Louisiana
Jan 23Elevance Health Offers Great Value
Jan 17At US$483, Is Elevance Health Inc. (NYSE:ELV) Worth Looking At Closely?
Jan 17Elevance Health: Strong And Steady EPS Growth Ahead, High Relative Strength Name
Jan 02Elevance Health (NYSE:ELV) Seems To Use Debt Rather Sparingly
Nov 28Does Elevance Health (NYSE:ELV) Deserve A Spot On Your Watchlist?
Nov 16Elevance Health to acquire speciality pharmacy from CarepathRx
Nov 09Elevance Health (NYSE:ELV) Is Doing The Right Things To Multiply Its Share Price
Nov 02Elevance Health declares $1.28 dividend
Oct 19Are Investors Undervaluing Elevance Health Inc. (NYSE:ELV) By 37%?
Oct 12Elevance affiliates to offer affordable Medicare Advantage plans
Oct 10Molina, Elevance, Centene win Medicare contracts in California
Aug 26Elevance Health (NYSE:ELV) Seems To Use Debt Rather Sparingly
Aug 25Gewinn- und Umsatzwachstumsprognosen
| Datum | Umsatz | Gewinne | Freier Cashflow | Bargeld aus operativen Tätigkeiten | Durchschn. Anz. Analysten |
|---|---|---|---|---|---|
| 12/31/2026 | 195,008 | 9,981 | 9,205 | 10,772 | 7 |
| 12/31/2025 | 182,396 | 9,070 | 9,090 | 12,579 | 13 |
| 12/31/2024 | 171,492 | 8,056 | 9,763 | 8,467 | 13 |
| 3/31/2024 | 171,745 | 6,244 | 2,296 | 3,570 | N/A |
| 12/31/2023 | 171,340 | 5,987 | 6,765 | 8,061 | N/A |
| 9/30/2023 | 168,626 | 6,127 | 8,246 | 9,514 | N/A |
| 6/30/2023 | 165,716 | 6,441 | 10,571 | 11,825 | N/A |
| 3/31/2023 | 160,676 | 6,094 | 11,128 | 12,327 | N/A |
| 12/31/2022 | 156,599 | 5,894 | 7,247 | 8,399 | N/A |
| 9/30/2022 | 153,251 | 6,166 | 10,395 | 11,589 | N/A |
| 6/30/2022 | 149,134 | 6,072 | 8,022 | 9,169 | N/A |
| 3/31/2022 | 144,353 | 6,228 | 7,263 | 8,400 | N/A |
| 12/31/2021 | 138,643 | 6,158 | 7,277 | 8,364 | N/A |
| 9/30/2021 | 133,883 | 5,518 | 9,480 | 10,505 | N/A |
| 6/30/2021 | 129,219 | 4,231 | 5,778 | 6,851 | N/A |
| 3/31/2021 | 124,632 | 4,714 | 9,657 | 10,678 | N/A |
| 12/31/2020 | 121,868 | 4,572 | 9,667 | 10,688 | N/A |
| 9/30/2020 | 117,449 | 4,955 | 7,108 | 8,202 | N/A |
| 6/30/2020 | 112,965 | 5,916 | 9,960 | 11,019 | N/A |
| 3/31/2020 | 109,167 | 4,779 | 5,899 | 6,946 | N/A |
| 12/31/2019 | 104,212 | 4,807 | 4,984 | 6,061 | N/A |
| 9/30/2019 | 100,165 | 4,298 | 4,151 | 5,197 | N/A |
| 6/30/2019 | 96,742 | 4,074 | 3,007 | 4,137 | N/A |
| 3/31/2019 | 94,220 | 3,989 | 2,018 | 3,242 | N/A |
| 12/31/2018 | 92,091 | 3,750 | 2,619 | 3,827 | N/A |
| 9/30/2018 | 91,409 | 4,556 | 891 | 2,063 | N/A |
| 6/30/2018 | 90,584 | 4,344 | 2,825 | 3,861 | N/A |
| 3/31/2018 | 90,061 | 4,145 | 2,822 | 3,712 | N/A |
| 12/31/2017 | 90,049 | 3,843 | N/A | 4,185 | N/A |
| 9/30/2017 | 89,055 | 2,980 | N/A | 5,763 | N/A |
| 6/30/2017 | 88,038 | 2,851 | N/A | 4,322 | N/A |
| 3/31/2017 | 87,083 | 2,777 | N/A | 4,599 | N/A |
| 12/31/2016 | 84,862 | 2,470 | N/A | 3,270 | N/A |
| 9/30/2016 | 83,364 | 2,282 | N/A | 3,943 | N/A |
| 6/30/2016 | 81,866 | 2,319 | N/A | 3,322 | N/A |
| 3/31/2016 | 80,412 | 2,398 | N/A | 3,825 | N/A |
| 12/31/2015 | 79,158 | 2,560 | N/A | 4,212 | N/A |
| 9/30/2015 | 77,959 | 2,886 | N/A | 3,472 | N/A |
| 6/30/2015 | 76,605 | 2,862 | N/A | 3,734 | N/A |
| 3/31/2015 | 75,066 | 2,734 | N/A | 3,632 | N/A |
| 12/31/2014 | 73,886 | 2,560 | N/A | 3,369 | N/A |
| 9/30/2014 | 72,792 | 2,362 | N/A | 3,337 | N/A |
| 6/30/2014 | 72,090 | 2,385 | N/A | 4,129 | N/A |
| 3/31/2014 | 71,307 | 2,453 | N/A | 3,483 | N/A |
| 12/31/2013 | 71,024 | 2,634 | N/A | 3,052 | N/A |
| 9/30/2013 | 68,443 | 2,785 | N/A | 3,539 | N/A |
| 6/30/2013 | 65,941 | 2,823 | N/A | 2,382 | N/A |
Analystenprognosen zum zukünftigen Wachstum
Einkommen vs. Sparrate: ELVDas prognostizierte Gewinnwachstum (12.3% pro Jahr) liegt über der Sparquote (2.4%).
Ertrag vs. Markt: ELVDie Erträge des Unternehmens (12.3% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt US (14.7% pro Jahr).
Hohe Wachstumserträge: ELVDie Erträge des Unternehmens werden voraussichtlich steigen, jedoch nicht deutlich.
Einnahmen vs. Markt: ELVDie Einnahmen des Unternehmens (5.1% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt US (8.4% pro Jahr).
Hohe Wachstumseinnahmen: ELVDie Einnahmen des Unternehmens (5.1% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.
Wachstumsprognosen für den Gewinn je Aktie
Künftige Eigenkapitalrendite
Künftige Eigenkapitalrendite: ELVDie Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich hoch sein (20.1%)